AIVD Biotech

AIVD carries out nanobodies for In Vitro diagnostic uses and academic research.

AIVD nanobody production service includes analysis of customer-provided antigen, antigen modification, immunization of one animal, library construction and screening, delivery of Bacterial Glycerol Stock of positive clones and antibodies sequences.

Workflow:

Phase I. Animal immunization. The phase includes antigen modification for immunization, immunization of one animal (alpaca) with client-provided antigen, blood collection (20 ml), and ELISA analysis, PBMC isolation and preservation. Turnaround period: 8-12 weeks.

Phase II. Phage Display Library Construction. Antibody cDNA generation via RNA isolation, PCR amplification, and diverse antibody library construction. Turnaround period: 3 weeks.

Phase III. Library Screening. Immune library Phage display screening, ELISA verification, identification of positive clones, antibody sequences. Turnaround period: 6 weeks.

AIVD offers customized library construction services under M13 filamentous phage display system. Our scientists are confident in generating high-quality libraries with a diversity of 10^8.

Requirements for provided antigens: polypeptide antigen: LC/MS analysis report, purity > 90 %, amount 10 mg: protein antigen: SDS-PAGE report, purity > 85 %, amount 2.8-10 mg, concentration > 0.5 mg/ml

AIVD offers small- and large-scale expression of proteins in E. coli. and Pichia Pastoris, nanobody labeling and etc.

AIVD is delighted to offer our clients protein production services tailored to their specific needs.

AIVD has extensive experience in protein production. We develop strategies in E. coli and Pichia Pastoris expression systems to produce desired proteins, such as VHH, recombinant protein, peptides specific for your applications. 

According to the project needs you can choose E.coli or yeast expression system to get your protein of interest. Our team can develop a customized protocol or adapt your protocol as well. We have produced many VHHs with high affinity and specificity against various targets. Single domain antibodies are perfectly stable and harboring the full antigen-binding capacity of conventional antibodies. This unique structural and functional property makes these molecules ideal candidates for a new generation of antibody therapeutics.

AIVD carries out mouse monoclonal antibodies development and production.

AIVD offers optimized and efficient protocols for immunizing mice, creating fusions, screening hybridomas, and delivering cell lines. 

AIVD has an onsite vivarium and working to establish a GMP facility soon, we also have a veterinarian staff to make sure our mice and other animals are in the best health. 

Workflow includes: 

 2) Antigen Preparation

 3) Mouse Immunization

 4) Hybridoma Fusion and Expansion 1

 5) Hybridoma Screening and Selection

 6) Hybridoma Subcloning, Screening and Selection

 7) Hybridoma Cryopreservation

 8) Antibody Purification and Testing

 9) CoA and Final Report